Eric J Lenze

11PUBLICATIONS
57CO-AUTHORS
Predictive and prognostic markersPharmaceutical delivery technologiesPharmacogenomicsVenereologyGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Apr 03, 2026
A deep-learning based biomarker of systemic cellular senescence burden to predict mortality and health outcomes.

Shangshu Zhao, Chia-Ling Kuo, Eric J Lenze

|Jul 04, 2025
High-Frequency, At-Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID-19 Treatment.

Eric J Lenze, Madeline Nykamp, J Philip Miller

|Jan 29, 2024
CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression.

Xiaoyu Men, Zachary L Taylor, Victoria S Marshe

|Aug 25, 2023
The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial.

Angela M Reiersen, Caline Mattar, Rachel A Bender Ignacio

|Oct 27, 2022
Mindfulness Training for Depressed Older Adults Using Smartphone Technology: Protocol for a Fully Remote Precision Clinical Trial.

Abigail Schweiger, Thomas L Rodebaugh, Eric J Lenze

|Feb 12, 2022
Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence".

Eric J Lenze, Angela M Reiersen, Shelley N Facente

Pageof 2

Frequent Collaborators

4 joint publications

Angela M Reiersen

4 joint publications

Ginger E Nicol

3 joint publications

J Philip Miller

2 joint publications

Thomas L Rodebaugh